Rxo (RXO) Restructuring Costs (2021 - 2026)

Rxo (RXO) has reported Restructuring Costs for 6 consecutive years, with $7.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Restructuring Costs rose 133.33% year-over-year to $7.0 million; the trailing twelve-month figure through Jun 2026 stood at $35.0 million (down 5.41% YoY), and the FY2025 full-year result was $38.0 million, up 15.15% from the prior year.
• Restructuring Costs steadied at $7.0 million in Q2 2026 per RXO's latest filing, from $7.0 million in the prior quarter.
• Across five years, Restructuring Costs topped out at $18.0 million in Q4 2024 and bottomed at $1.0 million in Q2 2023.
• Historically, Restructuring Costs has averaged $6.7 million across 5 years, with a median of $4.0 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Restructuring Costs jumped 500.0% in 2022, then tumbled 66.67% in 2023.
• Over 5 years, Restructuring Costs stood at $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then jumped by 350.0% to $18.0 million in 2024, then fell by 5.56% to $17.0 million in 2025, then sank by 58.82% to $7.0 million in 2026.
• According to Business Quant data, Restructuring Costs over the past three periods registered $7.0 million, $7.0 million, and $17.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.